J9215 HCPCS Level II code: Injection, interferon, alfa-n3, (human leukocyte derived), 250,000 iu

J9215 is the HCPCS code for “Injection, interferon, alfa-n3, (human leukocyte derived), 250,000 iu” in CMS’s October 2026 release, in effect from Oct 1, 2026.

Official description

J9215

Injection, interferon, alfa-n3, (human leukocyte derived), 250,000 iu

Short description: Interferon alfa-n3 inj

HCPCS · United States

Medicare details

The indicators CMS publishes with J9215 in its October 2026 file. They describe Medicare’s handling, not another payer’s.

Medicare coverage
Special coverage instructions apply
Medicare pricing
Drugs
Type of service
Immunosuppressive drugs
BETOS category
Chemotherapy
Added
Jan 1, 1993

Where J9215 sits

  1. 1J codesDrugs administered other than orally
  2. 2Active code J9215Injection, interferon, alfa-n3, (human leukocyte derived), 250,000 iu

Source and release

Data release
HCPCS Level II · October 2026
Effective date
Oct 1, 2026
Publisher
CMS

This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.

Frequently asked questions

What does HCPCS code J9215 mean?

J9215 is the HCPCS code for “Injection, interferon, alfa-n3, (human leukocyte derived), 250,000 iu” in CMS’s HCPCS Level II October 2026 release.

Does Medicare cover J9215?

CMS lists J9215’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.

Which HCPCS Level II release does this page use?

It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.